Heart Attack – Gout Drug May Reduce Risk

The University of Dundee study is the first stage in a major clinical trial to see whether allopurinol (commonly used for gout) can benefit people at high risk of cardiovascular events such as heart attacks.

The University of Dundee study is the first stage in a major clinical trial to see whether allopurinol (commonly used for gout) can benefit people at high risk of cardiovascular events such as heart attacks.It is already known that a strong link exists between the breakdown of the cells that line blood vessels, a process called endothelial dysfunction, and cardiovascular events such as heart attacks. And because allopurinol improves endothelial dysfunction, the researchers want to explore its potential benefits for heart patients.The scientists will first investigate the correct dose of the drug to optimize its effect on cells, a dose that will be used in future trials. This will include seeing whether low doses are associated no improvement, or a worsening of endothelial dysfunction. The researchers will also study the mechanisms behind allopurinols effect on endothelial dysfunction, including whether it is down to changes in uric acid and/or oxidative stress.Once we have identified the optimum dose and increased our understanding of the mechanisms underlying the drugs benefits, we will be well on our way to developing a potentially significant clinical trial to help heart patients in future, said Professor Allan Struthers.(Source: M.S.W.: ZoeMed: Cardiac Life Centre: 22nd August 2003)